Citius oncology expands distribution network for lymphir with execution of distribution services agreement with cencora

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for fda-approved immunotherapy lymphir™ cranford, n.j. , july 15, 2025 /prnewswire/ -- citius oncology, inc. ("citius oncology") (nasdaq: ctor), a majority-owned subsidiary of citius pharmaceuticals, inc. (nasdaq: ctxr), today announced the execution of a distribution services agreement with cencora (formerly amerisourcebergen), a global pharmaceutical services company.
COR Ratings Summary
COR Quant Ranking